Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Emivirine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.40 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Emivirine SCHEMBL4657810 | 1.00 | ALDH1A1 (0.43) | ALDH1A1CAPN1UPP1DAOHPGD | |
| SCHEMBL30601622 | 0.90 | ALDH1A1 (0.55) | ALDH1A1CAPN1UPP1DAOHPGD | |
| SCHEMBL7255992 | 0.86 | ALDH1A1 (0.40) | ALDH1A1CAPN1UPP1DAOHPGD | |
| SCHEMBL7258531 | 0.86 | ALDH1A1 (0.40) | ALDH1A1CAPN1UPP1DAOHPGD | |
| SCHEMBL23752310 | 0.85 | ALDH1A1 (0.34) | ALDH1A1DAOMEN1KMT2A | |
| SCHEMBL7255123 | 0.85 | ALDH1A1 (0.40) | ALDH1A1CAPN1UPP1DAOHPGD | |
| SCHEMBL7259644 | 0.84 | ALDH1A1 (0.39) | ALDH1A1CAPN1UPP1DAOHPGD | |
| SCHEMBL7255323 | 0.83 | ALDH1A1 (0.38) | ALDH1A1CAPN1UPP1DAOKDM5A | |
| SCHEMBL7255285 | 0.83 | TK1 (0.40) | ALDH1A1CAPN1UPP1DAOHPGD | |
| SCHEMBL598947 | 0.82 | ALDH1A1 (0.45) | ALDH1A1UPP1HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4685 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-3790536-B1 | NANOCONTAINERS FOR TRANSPORTING NONPOLAR, LIPOPHILIC SUBSTANCES SUCH AS ANTIBIOTICS | KARLSRUHER INST TECHNOLOGIE (DE) | 2026-04-22 | — | — | EP | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2025-11-06 | — | — | US | claimed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4566670-A2 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | Gilead Sciences, Inc. (US) | 2025-06-11 | — | — | EP | claimed |
| US-12220464-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-02-11 | — | — | US | claimed |
| US-20250025426-A1 | SYNERGISTIC TRANSPORT OF LIPOPHILIC AND HYDROPHILIC ACTIVE SUBSTANCES IN NANOPARTICLES | Karlsruher Institut für Technologie (DE) | 2025-01-23 | — | — | US | claimed |
| EP-1150956-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2001-11-07 | — | — | EP | claimed |
| WO-2001079246-A2 | 3'-OR 2'-HYDROXYMETHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR TREATMENT OF HEPATITIS VIRUS INFECTIONS | PHARMASSET, LTD. (BB) | 2001-10-25 | — | — | WO | claimed |
| US-6194391-B1 | CS-87 (TITLE COMPOUND) INDUCES A TRANSIENT MUTATION IN HIV-1 AT THE 70TH CODON OF THE REVERSE TRANSCRIPTASE REGION OF THE VIRUS; ADMINISTERING TO A HUMAN IN NEED OF THERAPY WITH A DRUG THAT INDUCES A MUTATION IN HIV-1 AT ANOTHER LOCATION | EMORY UNIVERSITY | 2001-02-27 | — | — | US | claimed |
| WO-2000061566-A1 | PROCESS FOR PREPARING MKC-442 | TRIANGLE PHARMACEUTICALS, INC. (US) | 2000-10-19 | — | — | WO | claimed |
| WO-2000047561-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2000-08-17 | — | — | WO | claimed |
| EP-1001789-A1 | PRODUCT COMPRISING AT LEAST A DOUBLE STRANDED RNA COMBINED WITH AT LEAST A 6-BENZYLURACIL DERIVATIVE | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2000-05-24 | — | — | EP | claimed |
| EP-0979650-A1 | ANTIVIRAL AGENTS | MITSUBISHI CHEMICAL CORPORATION (JP) | 2000-02-16 | — | — | EP | claimed |
| WO-1999007384-A1 | PRODUCT COMPRISING AT LEAST A DOUBLE STRANDED RNA COMBINED WITH AT LEAST A 6-BENZYLURACIL DERIVATIVE | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1999-02-18 | — | — | WO | claimed |
| US-5604209-A | COMBINATION OF 6-BENZYL-1-ETHOXYMETHYL-5-ISOPROPYLURACIL ANDDIDEOXYRIBONUCLEOSIDES; TREATING HUMAN IMMUNODEFICIENCY VIRUS | MITSUBISHI CHEMICAL CORPORATION (JP) | 1997-02-18 | — | — | US | claimed |
| EP-0631783-A1 | Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives | Mitsubishi Chemical Corporation (JP) | 1995-01-04 | — | — | EP | claimed |